CompletedNCT05322941
AEF0117 medication research for people with cannabis use concerns
About this title
Effect of AEF0117 on Treatment-seeking Patients With Cannabis Use Disorder (CUD)
Read the official source — NCT05322941Medication studyAges 18–65United StatesAddiction
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- Phoenix and 10 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: May 6, 2022
- Recruitment status
- Completed
- Enrollment listed in the registry
- 333
- Sponsor
- Aelis Farma
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT05322941
- Official title
Show the full official title
A Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel-group, Phase 2b Study in Treatment-seeking Patients With Cannabis Use Disorder to Assess the Efficacy, Safety, and Tolerability of AEF0117 in Reducing Cannabis Use
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Phoenix · Garden Grove · Los Angeles
8 more locations
- New Haven
- Lauderhill
- Miami Lakes
- New York
- Portland
- Charleston
- San Antonio
- Draper
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Aelis Farma.
Did this study involve medication?
Yes. The study involved medication, including AEF0117 and Placebo oral capsule.
Who was this study for?
Listed age limits: 18 years to 65 years.
